CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled / 10 target
Drug / intervention
Azithromycindrug
Likely dose
Azithromycin 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04287049
NCT04287049Phase 2CompletedUpdate Overdue (0.1/mo)Completion was 15mo ago
CompareCT.gov

Early Bactericidal Activity of Standard Drugs Used to Treat Mycobacterium Avium Complex: a Pilot Study

Johns Hopkins University·interventional·Posted Feb 27, 2020·Updated Jun 22, 2026

In Brief

A Phase 2 clinical trial evaluating Azithromycin for Mycobacterium Avium Complex. Completed, enrolled 10 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMycobacterium Avium Complex
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), American College of Chest Physicians

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 27, 2020
Enrollment StartFeb 24, 2020
Primary CompletionMar 21, 2025
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 6.3 years ago

Arms & Interventions

14 Day Azithromycin Monotherapyexperimental

For the first 14 days of therapy, participants will receive Azithromycin 250mg by mouth (PO) daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.

Drug: Azithromycin

Interventions

Azithromycindrug

Azithromycin 250 mg PO daily